{"ticker": {"uuid": "0942b8b2-2d0e-4b10-9d02-b2fbd18a9650", "symbol": "PLRX", "name": "Pliant Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 Pliant Therapeutics Inc For: 13 July By Investing.com", "summary": "This article reports on a Form 4 filing for Pliant Therapeutics Inc (PLRX) for July 13. Form 4s detail changes in beneficial ownership of company stock by insiders. The article, however, does not provide specific details from the Form 4 filing itself beyond noting its existence.", "url": "https://ng.investing.com/news/stock-market-news/form-4-pliant-therapeuticsinc-for-13-july-93CH-2597540", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T23:42:21", "published_display": "13 Jul 2026 23:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors", "summary": "Pliant Therapeutics has announced the appointment of Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments are expected to strengthen the company's strategic leadership as it continues to advance its therapeutic pipeline.", "url": "https://www.moomoo.com/news/post/72861411/press-release-pliant-therapeutics-names-flavia-borellini-phd-and-robert?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T21:10:15", "published_display": "13 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] PLIANT THERAPEUTICS, INC. Reports Material Event", "summary": "Pliant Therapeutics, Inc. expanded its Board of Directors from seven to nine members on July 9, 2026, appointing Robert Iannone, M.D., M.S.C.E. and Flavia Borellini, Ph.D. as independent directors. Both new directors receive annual retainers and stock options, with Dr. Borellini ", "url": "https://www.stocktitan.net/sec-filings/PLRX/8-k-pliant-therapeutics-inc-reports-material-event-cb9218202535.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) director files initial insider ownership statement", "summary": "Pliant Therapeutics director Borellini Flavia has filed an initial statement of beneficial ownership (Form 3) as a director according to an SEC filing. The filing indicates no equity transactions or derivative positions, solely disclosing her insider status. This is a neutral fil", "url": "https://www.stocktitan.net/sec-filings/PLRX/form-3-pliant-therapeutics-inc-initial-statement-of-beneficial-owners-482831629332.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (NASDAQ: PLRX) grants 60,000 options to director Iannone", "summary": "Pliant Therapeutics (NASDAQ: PLRX) has granted 60,000 stock options to director Robert Iannone on July 9, 2026. The options have an exercise price of $1.13 per share and will expire on July 9, 2036. The vesting schedule dictates that 1/36th of the options will vest monthly, conti", "url": "https://www.stocktitan.net/sec-filings/PLRX/form-4-pliant-therapeutics-inc-insider-trading-activity-f28da9b8865c.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) director Robert Iannone submits initial Form 3", "summary": "Pliant Therapeutics, Inc. (PLRX) director Robert Iannone has submitted an initial statement of beneficial ownership on Form 3. The filing indicates no reported transactions such as purchases, sales, or derivative exercises by Iannone. This Form 3 filing serves to officially discl", "url": "https://www.stocktitan.net/sec-filings/PLRX/form-3-pliant-therapeutics-inc-initial-statement-of-beneficial-owners-1d1cb6312576.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) awards 60,000 stock options to director Flavia Borellini", "summary": "Pliant Therapeutics (PLRX) has granted 60,000 stock options to director Flavia Borellini. The options, with an exercise price of $1.13 per share and an expiration date of July 9, 2036, will vest monthly over a 36-month period, contingent on her continued service. This grant is a ", "url": "https://www.stocktitan.net/sec-filings/PLRX/form-4-pliant-therapeutics-inc-insider-trading-activity-058029143c8e.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors", "summary": "Pliant Therapeutics has appointed Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments bring extensive global oncology drug development, regulatory, and operational expertise to the company. The new board members are expected ", "url": "https://investingnews.com/pliant-therapeutics-names-flavia-borellini-ph-d-and-robert-iannone-m-d-m-s-c-e-to-board-of-directors/", "source_name": "Investing News Network", "published_at": "2026-07-13T14:42:21", "published_display": "13 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics adds two directors with oncology expertise", "summary": "Pliant Therapeutics, Inc. has expanded its Board of Directors with the appointment of Dr. Flavia Borellini and Dr. Robert Iannone, both bringing extensive oncology drug development experience. The company is a clinical-stage biopharmaceutical firm currently developing integrin-ba", "url": "https://www.investing.com/news/company-news/pliant-therapeutics-adds-two-directors-with-oncology-expertise-93CH-4788518", "source_name": "Investing.com", "published_at": "2026-07-13T13:40:13", "published_display": "13 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two cancer drug veterans join Pliant Therapeutics\u2019 board to guide PLN-101095", "summary": "Pliant Therapeutics (Nasdaq: PLRX) has appointed Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments bring extensive global oncology drug development, regulatory, and operational expertise to the company as it advances its in", "url": "https://www.stocktitan.net/news/PLRX/pliant-therapeutics-names-flavia-borellini-ph-d-and-robert-iannone-m-6ox6e6kayplo.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:40:12", "published_display": "13 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of Pliant Therapeutics, Inc. \u2013 NASDAQ:PLRX", "summary": "This page provides financial data, specifically the price to sales forward, for Pliant Therapeutics, Inc. (NASDAQ: PLRX). It details no trades, indicating a market closure, and highlights access to various financial tools and market data services.", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T10:39:44", "published_display": "12 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pliant Therapeutics, Inc. \u2013 FWB:9PT", "summary": "This article provides the \"Price to earnings forward\" for Pliant Therapeutics, Inc. (FWB:9PT) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades recorded. The content is primarily a data point rather than an analytical article.", "url": "https://www.tradingview.com/symbols/FWB-9PT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T07:40:40", "published_display": "11 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pliant Therapeutics, Inc. \u2013 FWB:9PT", "summary": "This article provides a financial overview and enterprise value to revenue forward for Pliant Therapeutics, Inc. (FWB:9PT) on the Frankfurt Stock Exchange. It indicates no recent trades for the company and is part of a larger financial data and trading platform.", "url": "https://www.tradingview.com/symbols/FWB-9PT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T00:39:54", "published_display": "11 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pliant Therapeutics, Inc. \u2013 TRADEGATE:9PT", "summary": "This article provides a financial overview of Pliant Therapeutics, Inc. (TRADEGATE:9PT), focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data point from a financial platform, showing that no trades have occurred and the market is closed for ", "url": "https://www.tradingview.com/symbols/TRADEGATE-9PT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:10:33", "published_display": "09 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock Edges Lower, Holds Closely Above Key Support - Accumulation Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQVJFLUhqMnlEY1ExclFGNEZubDl5b3ZZUk1ma2s1MTNjZDlDRkhFZ19taVhLdmJXSlJKUWx3NFYzMjNQR3plNzlqVkNwb0tOajQwMHhpeHo4QnpZaG1ULXc2TXpBYjdsOHFhUl9lc0F4N1M5d0xoT21INnl1MDZMaUlYV3FweWstZE5YT2RZNjg4eVNqWmZ3ZXdQaU1hb1A1cnE4Q2tNMGNjNHl5UzlXM3RHREoxREk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-09T16:43:45+00:00", "published_display": "09 Jul 2026 16:43", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. \u2013 NASDAQ:PLRX", "summary": "This article provides access to the \"Enterprise value to EBITDA forward\"", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T07:39:42", "published_display": "06 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. \u2013 GETTEX:9PT", "summary": "This article displays the \"Enterprise value to EBITDA forward\" metric for Pliant Therapeutics, Inc. (GETTEX:9PT) on TradingView. It appears to be a financial data page rather than a descriptive article, showing no specific value for the metric but presenting the company's financi", "url": "https://www.tradingview.com/symbols/GETTEX-9PT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T07:09:39", "published_display": "05 Jul 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Pliant Therapeutics, Inc. \u2013 NASDAQ:PLRX", "summary": "The article focuses on Pliant Therapeutics, Inc. (NASDAQ: PLRX) and its enterprise value to EBIT forward. It presents financial data related to the company within the TradingView platform, noting that the market was closed at the time of viewing with no trades. The content primar", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T01:10:12", "published_display": "03 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRX Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides an analysis of Pliant Therapeutics Inc. (PLRX) financials, focusing on its revenue, profitability margins (gross, operating, net), and Return on Equity. It also benchmarks PLRX against competitors IMMP and XBIT, highlighting its market capitalization and com", "url": "https://intellectia.ai/en/stock/PLRX/financials", "source_name": "Intellectia AI", "published_at": "2026-06-30T03:10:09", "published_display": "30 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLRX)", "summary": "This article provides financial actuals and estimates for Pliant Therapeutics, Inc. (NASDAQ:PLRX), highlighting its current stock price, market capitalization, and analyst forecasts. It includes details on past performance, revenue, earnings, and upcoming earnings report dates, e", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:43", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "9PT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Pliant Therapeutics, Inc. (9PT) stock, including analyst price targets, historical highs and lows, and upcoming earnings dates. It also details the company's financial performance, such as EPS, revenue, and net income, and confirms that 9PT do", "url": "https://www.tradingview.com/symbols/FWB-9PT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:41:22", "published_display": "25 Jun 2026 22:41", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Pliant Therapeutics, Inc. (PLRX) stock, including analyst price targets and ratings. It details the company's current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also includes a brief FAQ", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:41", "published_display": "25 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Pliant Therapeutics Inc (PLRX), stating that relevant financial data for FY2024 and FY2025 has not yet been disclosed by the company. It primarily highlights the lack of available information regarding revenue by regio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T17:10:13", "published_display": "19 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "The article details the shareholder structure of Pliant Therapeutics Inc (PLRX), identifying its major shareholders and institutional holdings. It lists the top individual shareholders like Tang Capital Management and Citadel Advisors, along with their respective proportions. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:38", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Pliant Therapeutics Inc (PLRX) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split history. The page also presents current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:10", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Institutional Confidence", "summary": "Pliant Therapeutics Inc (PLRX) has an institutional shareholding score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 81.81%, a 4.56% decrease quarter-over-quarter. James Simons is the largest institutional shareh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:10", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Pliant Therapeutics Inc (PLRX) as of June 17, 2026. The company currently holds a valuation score of 8.42, ranking 96 out of 157 in the Pharmaceuticals industry. Key financial ratios like P/E, P/B, P/S, and P/CF are mentioned, though ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:31", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Pliant Therapeutics Inc (PLRX) has an earnings forecast score of 6.00, placing it 132nd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $3.50, with a range from $2.00 to $4.00, indicating a potential upside of 124.09%. The company's stock ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T19:11:05", "published_display": "17 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pliant Therapeutics Inc (PLRX), detailing its price momentum, support and resistance levels, and indicator readings. The stock currently has a price momentum score of 3.93, suggesting it's suitable for range-bound swing trading betwee", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/technical", "source_name": "TradingKey", "published_at": "2026-06-16T22:11:05", "published_display": "16 Jun 2026 22:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains, Biotech Sector Weakness Persists - Schiff Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOOEEtTkZRNDBJTEpSWDI5VmllRzJ3UXkzRFVEaUE0T1dkQmlCbjY1RHphSXlZa3F2S3NFTlhWTEM5WG5mQ0pEcE5YRi0tZkJfRllhQ0tQVEdGdjBzLXdIUVc1YUFpTFdTZDRNdEkxM3l2Tkh3WFFDc2huU1QxWms0VXVCRmdMTllpMllyX3p6RE55Z1lXLVJtOXpUTFdpYmhwZW1Kak52a0xfRUZ2OXlYdHJnbGQ5M3FQZ1l5VlhjUWpZaW5yRFJib25xT01CZzVmdUE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pliant-therapeutics-provides-corporate-reports-200500848.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:05:00+00:00", "published_display": "11 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pliant-therapeutics-participate-rbc-capital-123000378.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:30:00+00:00", "published_display": "06 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant CEO, CFO to join RBC healthcare fireside chat on May 19", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQOG9XZFFxWWhuWnFZWm84Rmo0LTJGaGE1QmRKMl9Ib3k5STQ1STRRMWVNVUd6QVJxUE9VUmExbUJXOWpMaDhYU3FJQ3RremZ0dmZGanlsWHViUEV2amtTTHo5SXhVeV9DNGxET1BWb2trV3BHNDBDdFRaeWR2Nm1LZzRGUE5KdjlTQVNPMERTQWVRZ0pCTjVBSkN4ZFExOE1QZlB0YXUweUl2M2t2Y0djNm9CaWhKSnZfUUVPenh0WXo?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating\u00a0PLN-101095 in Patients with ICI-Refractory Solid Tumors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pliant-therapeutics-announces-first-patient-123000577.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T12:30:00+00:00", "published_display": "30 Apr 2026 12:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMVF4ajR2Y0h1NWN0bzV1T3dXR0ItS3NsbnMwaDFYRjQwM1hWNFBLUWhyeFVMR01nYTZCZHM1UFlkbXhNMkRJMi1zQnlkQXlHUzRvV2cwR2NyOVhLb0V0RFJNdTF2VzJ0UkIyRDdVakdXTzhqbzR4RkdlcnVhNWZaTmVEMFdxTTB3T0pOQU1ZSldNbW1NV1lyVUJaOGRpemNKbkoxQzJ6OXlZNTR6d25JdHROXzkyOENZMlN0ZmRqQk4?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9iMWN4R0E4RlZ4RFFGN0lFSzd4ZWxGU3hOZWZ0aDFzS21BRS1nOVgydXRMQXNJU09BTER6WXV6aWVEOVlTM25uMHBjcXA3eDRqMVVz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:32:44+00:00", "published_display": "25 Apr 2025 00:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock Forecast and Price Target 2026 $PLRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE12Sk9DNHFqdDFhWVd4NGJXS01WbTZNc1k0czZld0lWcGY1akt6U1FKbk9NeEMwTUM2ZmZpRVFpYWNrTU9hbDBZSUVXSWxtY213OWtuYTRvQW5iUzd1aTFyTmVxTlMxdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:42:24+00:00", "published_display": "11 May 2024 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRX Stock Price and Chart \u2014 NASDAQ:PLRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE16WkdZdnRQMnU5SlB2Mm5mS0plcUduUmRGYzF1RUl1Rm5Ha3lvb3BEUVVoWnl4Mzg3dkJGNUl6eEV2dHhfeVZDX1dUUER4S083UlpxM3RvUEx4alYz?oc=5", "source_name": "TradingView", "published_at": "2023-01-23T08:00:00+00:00", "published_display": "23 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE01bTd2Z2tjS3RKUU1vaXAxQ3F4WEdhVExFT3VZSUNTZm1PaUJ5Ri1DeFVmNVNaekdkbFNNYjR4NEFVQWNrNlhmQXpZU2tuQQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-13T13:24:20+00:00", "published_display": "13 Sep 2020 13:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock Price, News & Analysis $PLRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1abFBJWDYxLUd2aVNZcnpFdllrWmM0bFBqQnladkRTWGQxaFdfVElLcG1reDllV25sRlA3X0dTOWdNOE5qQkdqc3ZDRlpHMFltWGx2ck43NzZHQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-06-10T20:15:28+00:00", "published_display": "10 Jun 2020 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRX: Pliant Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE1lQWdYTlU1VGZ4S1NweV9DV1MteTRMeXJEaWdLaHRoUE9MS3BLUU5iTFdRUE9PRVhpdnB3NDVPRERrcG5qMTZxTXpB?oc=5", "source_name": "Stocktwits", "published_at": "2020-06-03T03:56:48+00:00", "published_display": "03 Jun 2020 03:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Announces Pricing of Initial Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQV1NxNFc3MzNDSDRVa0g2ak5IdjloN0ltbld4TzJOVHV6UkxRd0JtX0JQOFVaQk1fTGZKVzl1QjFUZkFFblRuQXc5ekd2aDBkaGwxZURrTEtBNnpoNFRKTjUtOVp4SUhFbkZfNURsVEp6dnhHTXlCYnlKUkxJYTZoRWdaV3JzaTF0OWRTWXhjMUZsMG9icEs4TkRJV1NIblJ6eXVicWZZdjV3WVdqZWZmZU8zY1hOZ3k3M0h3Tg?oc=5", "source_name": "PR Newswire", "published_at": "2020-06-02T07:00:00+00:00", "published_display": "02 Jun 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 4 Pliant Therapeutics Inc For: 13 July By Investing.com", "summary": "This article reports on a Form 4 filing for Pliant Therapeutics Inc (PLRX) for July 13. Form 4s detail changes in beneficial ownership of company stock by insiders. The article, however, does not provide specific details from the Form 4 filing itself beyond noting its existence.", "url": "https://ng.investing.com/news/stock-market-news/form-4-pliant-therapeuticsinc-for-13-july-93CH-2597540", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T23:42:21", "published_display": "13 Jul 2026 23:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors", "summary": "Pliant Therapeutics has announced the appointment of Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments are expected to strengthen the company's strategic leadership as it continues to advance its therapeutic pipeline.", "url": "https://www.moomoo.com/news/post/72861411/press-release-pliant-therapeutics-names-flavia-borellini-phd-and-robert?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T21:10:15", "published_display": "13 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] PLIANT THERAPEUTICS, INC. Reports Material Event", "summary": "Pliant Therapeutics, Inc. expanded its Board of Directors from seven to nine members on July 9, 2026, appointing Robert Iannone, M.D., M.S.C.E. and Flavia Borellini, Ph.D. as independent directors. Both new directors receive annual retainers and stock options, with Dr. Borellini ", "url": "https://www.stocktitan.net/sec-filings/PLRX/8-k-pliant-therapeutics-inc-reports-material-event-cb9218202535.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) director files initial insider ownership statement", "summary": "Pliant Therapeutics director Borellini Flavia has filed an initial statement of beneficial ownership (Form 3) as a director according to an SEC filing. The filing indicates no equity transactions or derivative positions, solely disclosing her insider status. This is a neutral fil", "url": "https://www.stocktitan.net/sec-filings/PLRX/form-3-pliant-therapeutics-inc-initial-statement-of-beneficial-owners-482831629332.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (NASDAQ: PLRX) grants 60,000 options to director Iannone", "summary": "Pliant Therapeutics (NASDAQ: PLRX) has granted 60,000 stock options to director Robert Iannone on July 9, 2026. The options have an exercise price of $1.13 per share and will expire on July 9, 2036. The vesting schedule dictates that 1/36th of the options will vest monthly, conti", "url": "https://www.stocktitan.net/sec-filings/PLRX/form-4-pliant-therapeutics-inc-insider-trading-activity-f28da9b8865c.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) director Robert Iannone submits initial Form 3", "summary": "Pliant Therapeutics, Inc. (PLRX) director Robert Iannone has submitted an initial statement of beneficial ownership on Form 3. The filing indicates no reported transactions such as purchases, sales, or derivative exercises by Iannone. This Form 3 filing serves to officially discl", "url": "https://www.stocktitan.net/sec-filings/PLRX/form-3-pliant-therapeutics-inc-initial-statement-of-beneficial-owners-1d1cb6312576.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) awards 60,000 stock options to director Flavia Borellini", "summary": "Pliant Therapeutics (PLRX) has granted 60,000 stock options to director Flavia Borellini. The options, with an exercise price of $1.13 per share and an expiration date of July 9, 2036, will vest monthly over a 36-month period, contingent on her continued service. This grant is a ", "url": "https://www.stocktitan.net/sec-filings/PLRX/form-4-pliant-therapeutics-inc-insider-trading-activity-058029143c8e.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:42:21", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors", "summary": "Pliant Therapeutics has appointed Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments bring extensive global oncology drug development, regulatory, and operational expertise to the company. The new board members are expected ", "url": "https://investingnews.com/pliant-therapeutics-names-flavia-borellini-ph-d-and-robert-iannone-m-d-m-s-c-e-to-board-of-directors/", "source_name": "Investing News Network", "published_at": "2026-07-13T14:42:21", "published_display": "13 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics adds two directors with oncology expertise", "summary": "Pliant Therapeutics, Inc. has expanded its Board of Directors with the appointment of Dr. Flavia Borellini and Dr. Robert Iannone, both bringing extensive oncology drug development experience. The company is a clinical-stage biopharmaceutical firm currently developing integrin-ba", "url": "https://www.investing.com/news/company-news/pliant-therapeutics-adds-two-directors-with-oncology-expertise-93CH-4788518", "source_name": "Investing.com", "published_at": "2026-07-13T13:40:13", "published_display": "13 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two cancer drug veterans join Pliant Therapeutics\u2019 board to guide PLN-101095", "summary": "Pliant Therapeutics (Nasdaq: PLRX) has appointed Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments bring extensive global oncology drug development, regulatory, and operational expertise to the company as it advances its in", "url": "https://www.stocktitan.net/news/PLRX/pliant-therapeutics-names-flavia-borellini-ph-d-and-robert-iannone-m-6ox6e6kayplo.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:40:12", "published_display": "13 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pliant Therapeutics, Inc. \u2013 NASDAQ:PLRX", "summary": "This page provides financial data, specifically the price to sales forward, for Pliant Therapeutics, Inc. (NASDAQ: PLRX). It details no trades, indicating a market closure, and highlights access to various financial tools and market data services.", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T10:39:44", "published_display": "12 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pliant Therapeutics, Inc. \u2013 FWB:9PT", "summary": "This article provides the \"Price to earnings forward\" for Pliant Therapeutics, Inc. (FWB:9PT) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades recorded. The content is primarily a data point rather than an analytical article.", "url": "https://www.tradingview.com/symbols/FWB-9PT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T07:40:40", "published_display": "11 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pliant Therapeutics, Inc. \u2013 FWB:9PT", "summary": "This article provides a financial overview and enterprise value to revenue forward for Pliant Therapeutics, Inc. (FWB:9PT) on the Frankfurt Stock Exchange. It indicates no recent trades for the company and is part of a larger financial data and trading platform.", "url": "https://www.tradingview.com/symbols/FWB-9PT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T00:39:54", "published_display": "11 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pliant Therapeutics, Inc. \u2013 TRADEGATE:9PT", "summary": "This article provides a financial overview of Pliant Therapeutics, Inc. (TRADEGATE:9PT), focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data point from a financial platform, showing that no trades have occurred and the market is closed for ", "url": "https://www.tradingview.com/symbols/TRADEGATE-9PT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:10:33", "published_display": "09 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock Edges Lower, Holds Closely Above Key Support - Accumulation Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQVJFLUhqMnlEY1ExclFGNEZubDl5b3ZZUk1ma2s1MTNjZDlDRkhFZ19taVhLdmJXSlJKUWx3NFYzMjNQR3plNzlqVkNwb0tOajQwMHhpeHo4QnpZaG1ULXc2TXpBYjdsOHFhUl9lc0F4N1M5d0xoT21INnl1MDZMaUlYV3FweWstZE5YT2RZNjg4eVNqWmZ3ZXdQaU1hb1A1cnE4Q2tNMGNjNHl5UzlXM3RHREoxREk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-09T16:43:45+00:00", "published_display": "09 Jul 2026 16:43", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. \u2013 NASDAQ:PLRX", "summary": "This article provides access to the \"Enterprise value to EBITDA forward\"", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T07:39:42", "published_display": "06 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. \u2013 GETTEX:9PT", "summary": "This article displays the \"Enterprise value to EBITDA forward\" metric for Pliant Therapeutics, Inc. (GETTEX:9PT) on TradingView. It appears to be a financial data page rather than a descriptive article, showing no specific value for the metric but presenting the company's financi", "url": "https://www.tradingview.com/symbols/GETTEX-9PT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T07:09:39", "published_display": "05 Jul 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Pliant Therapeutics, Inc. \u2013 NASDAQ:PLRX", "summary": "The article focuses on Pliant Therapeutics, Inc. (NASDAQ: PLRX) and its enterprise value to EBIT forward. It presents financial data related to the company within the TradingView platform, noting that the market was closed at the time of viewing with no trades. The content primar", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T01:10:12", "published_display": "03 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRX Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides an analysis of Pliant Therapeutics Inc. (PLRX) financials, focusing on its revenue, profitability margins (gross, operating, net), and Return on Equity. It also benchmarks PLRX against competitors IMMP and XBIT, highlighting its market capitalization and com", "url": "https://intellectia.ai/en/stock/PLRX/financials", "source_name": "Intellectia AI", "published_at": "2026-06-30T03:10:09", "published_display": "30 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLRX)", "summary": "This article provides financial actuals and estimates for Pliant Therapeutics, Inc. (NASDAQ:PLRX), highlighting its current stock price, market capitalization, and analyst forecasts. It includes details on past performance, revenue, earnings, and upcoming earnings report dates, e", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:43", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "9PT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Pliant Therapeutics, Inc. (9PT) stock, including analyst price targets, historical highs and lows, and upcoming earnings dates. It also details the company's financial performance, such as EPS, revenue, and net income, and confirms that 9PT do", "url": "https://www.tradingview.com/symbols/FWB-9PT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:41:22", "published_display": "25 Jun 2026 22:41", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Pliant Therapeutics, Inc. (PLRX) stock, including analyst price targets and ratings. It details the company's current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also includes a brief FAQ", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:41", "published_display": "25 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Pliant Therapeutics Inc (PLRX), stating that relevant financial data for FY2024 and FY2025 has not yet been disclosed by the company. It primarily highlights the lack of available information regarding revenue by regio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T17:10:13", "published_display": "19 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "The article details the shareholder structure of Pliant Therapeutics Inc (PLRX), identifying its major shareholders and institutional holdings. It lists the top individual shareholders like Tang Capital Management and Citadel Advisors, along with their respective proportions. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:38", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Pliant Therapeutics Inc (PLRX) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split history. The page also presents current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:10", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Institutional Confidence", "summary": "Pliant Therapeutics Inc (PLRX) has an institutional shareholding score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 81.81%, a 4.56% decrease quarter-over-quarter. James Simons is the largest institutional shareh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:10", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Pliant Therapeutics Inc (PLRX) as of June 17, 2026. The company currently holds a valuation score of 8.42, ranking 96 out of 157 in the Pharmaceuticals industry. Key financial ratios like P/E, P/B, P/S, and P/CF are mentioned, though ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:31", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Pliant Therapeutics Inc (PLRX) has an earnings forecast score of 6.00, placing it 132nd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $3.50, with a range from $2.00 to $4.00, indicating a potential upside of 124.09%. The company's stock ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T19:11:05", "published_display": "17 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Inc (PLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pliant Therapeutics Inc (PLRX), detailing its price momentum, support and resistance levels, and indicator readings. The stock currently has a price momentum score of 3.93, suggesting it's suitable for range-bound swing trading betwee", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrx/technical", "source_name": "TradingKey", "published_at": "2026-06-16T22:11:05", "published_display": "16 Jun 2026 22:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains, Biotech Sector Weakness Persists - Schiff Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOOEEtTkZRNDBJTEpSWDI5VmllRzJ3UXkzRFVEaUE0T1dkQmlCbjY1RHphSXlZa3F2S3NFTlhWTEM5WG5mQ0pEcE5YRi0tZkJfRllhQ0tQVEdGdjBzLXdIUVc1YUFpTFdTZDRNdEkxM3l2Tkh3WFFDc2huU1QxWms0VXVCRmdMTllpMllyX3p6RE55Z1lXLVJtOXpUTFdpYmhwZW1Kak52a0xfRUZ2OXlYdHJnbGQ5M3FQZ1l5VlhjUWpZaW5yRFJib25xT01CZzVmdUE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pliant-therapeutics-provides-corporate-reports-200500848.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:05:00+00:00", "published_display": "11 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pliant-therapeutics-participate-rbc-capital-123000378.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:30:00+00:00", "published_display": "06 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant CEO, CFO to join RBC healthcare fireside chat on May 19", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQOG9XZFFxWWhuWnFZWm84Rmo0LTJGaGE1QmRKMl9Ib3k5STQ1STRRMWVNVUd6QVJxUE9VUmExbUJXOWpMaDhYU3FJQ3RremZ0dmZGanlsWHViUEV2amtTTHo5SXhVeV9DNGxET1BWb2trV3BHNDBDdFRaeWR2Nm1LZzRGUE5KdjlTQVNPMERTQWVRZ0pCTjVBSkN4ZFExOE1QZlB0YXUweUl2M2t2Y0djNm9CaWhKSnZfUUVPenh0WXo?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating\u00a0PLN-101095 in Patients with ICI-Refractory Solid Tumors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pliant-therapeutics-announces-first-patient-123000577.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T12:30:00+00:00", "published_display": "30 Apr 2026 12:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMVF4ajR2Y0h1NWN0bzV1T3dXR0ItS3NsbnMwaDFYRjQwM1hWNFBLUWhyeFVMR01nYTZCZHM1UFlkbXhNMkRJMi1zQnlkQXlHUzRvV2cwR2NyOVhLb0V0RFJNdTF2VzJ0UkIyRDdVakdXTzhqbzR4RkdlcnVhNWZaTmVEMFdxTTB3T0pOQU1ZSldNbW1NV1lyVUJaOGRpemNKbkoxQzJ6OXlZNTR6d25JdHROXzkyOENZMlN0ZmRqQk4?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9iMWN4R0E4RlZ4RFFGN0lFSzd4ZWxGU3hOZWZ0aDFzS21BRS1nOVgydXRMQXNJU09BTER6WXV6aWVEOVlTM25uMHBjcXA3eDRqMVVz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:32:44+00:00", "published_display": "25 Apr 2025 00:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock Forecast and Price Target 2026 $PLRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE12Sk9DNHFqdDFhWVd4NGJXS01WbTZNc1k0czZld0lWcGY1akt6U1FKbk9NeEMwTUM2ZmZpRVFpYWNrTU9hbDBZSUVXSWxtY213OWtuYTRvQW5iUzd1aTFyTmVxTlMxdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:42:24+00:00", "published_display": "11 May 2024 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRX Stock Price and Chart \u2014 NASDAQ:PLRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE16WkdZdnRQMnU5SlB2Mm5mS0plcUduUmRGYzF1RUl1Rm5Ha3lvb3BEUVVoWnl4Mzg3dkJGNUl6eEV2dHhfeVZDX1dUUER4S083UlpxM3RvUEx4alYz?oc=5", "source_name": "TradingView", "published_at": "2023-01-23T08:00:00+00:00", "published_display": "23 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE01bTd2Z2tjS3RKUU1vaXAxQ3F4WEdhVExFT3VZSUNTZm1PaUJ5Ri1DeFVmNVNaekdkbFNNYjR4NEFVQWNrNlhmQXpZU2tuQQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-13T13:24:20+00:00", "published_display": "13 Sep 2020 13:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics (PLRX) Stock Price, News & Analysis $PLRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1abFBJWDYxLUd2aVNZcnpFdllrWmM0bFBqQnladkRTWGQxaFdfVElLcG1reDllV25sRlA3X0dTOWdNOE5qQkdqc3ZDRlpHMFltWGx2ck43NzZHQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-06-10T20:15:28+00:00", "published_display": "10 Jun 2020 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRX: Pliant Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE1lQWdYTlU1VGZ4S1NweV9DV1MteTRMeXJEaWdLaHRoUE9MS3BLUU5iTFdRUE9PRVhpdnB3NDVPRERrcG5qMTZxTXpB?oc=5", "source_name": "Stocktwits", "published_at": "2020-06-03T03:56:48+00:00", "published_display": "03 Jun 2020 03:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pliant Therapeutics Announces Pricing of Initial Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQV1NxNFc3MzNDSDRVa0g2ak5IdjloN0ltbld4TzJOVHV6UkxRd0JtX0JQOFVaQk1fTGZKVzl1QjFUZkFFblRuQXc5ekd2aDBkaGwxZURrTEtBNnpoNFRKTjUtOVp4SUhFbkZfNURsVEp6dnhHTXlCYnlKUkxJYTZoRWdaV3JzaTF0OWRTWXhjMUZsMG9icEs4TkRJV1NIblJ6eXVicWZZdjV3WVdqZWZmZU8zY1hOZ3k3M0h3Tg?oc=5", "source_name": "PR Newswire", "published_at": "2020-06-02T07:00:00+00:00", "published_display": "02 Jun 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 85, "total_relevant": 51, "sentiment_summary": {"positive": 10, "negative": 4, "neutral": 37, "score": 53, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.15, "latest_week": "2026-07-17", "one_week_move": 2.7, "four_week_move": -0.9, "twelve_week_move": -7.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.14735, "market_dynamics_buy_signal": false, "relative_strength": -24.815271, "fair_value_gap": -85.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.1391, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.7% over one week, -0.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 9}, {"label": "TradingKey", "count": 7}, {"label": "Market source", "count": 6}, {"label": "GlobeNewswire", "count": 3}, {"label": "dars.gov.et", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "MarketBeat", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.7% over one week, -0.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 4 Pliant Therapeutics Inc For: 13 July By Investing.com"}], "updated_at": "2026-07-22T05:46:15.810640+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}